Richard N. Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, Elke Hunsche, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Tomás Pulido, Lewis J. Rubin, B.K.S. Sastry, Gérald Simonneau, Olivier Sitbon, Rogério Souza, Adam Torbicki and Nazzareno Galiè
Patient Subgroup Analyses on the Time to First PAH-Related Hospitalization
Patient subgroup analyses of the effect of 3 mg of macitentan (A) and 10 mg of macitentan (B) on the time to first PAH-related hospitalization. *”Other” causes consist of idiopathic or heritable PAH or PAH related to human immunodeficiency virus infection or drugs and toxins. Abbreviation as in Figure 2.